No black box warning on record for Aranesp

As of the latest FDA labeling reviewed, Aranesp (DARBEPOETIN ALFA) does not carry a black box warning. Standard warnings and precautions still apply — see the full Aranesp medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism: Using Aranesp to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit ( 5.1 and 14.1 ). Use caution in patients with coexistent cardiovascular disease and stroke ( 5.1 ). Increased Mortal

No black box warning on record for Aranesp

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism: Using Aranesp to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit ( 5.1 and 14.1 ). Use caution in patients with coexistent cardiovascular disease and stroke ( 5.1 ). Increased Mortal

Aranesp Black Box Warning

No black box warning on record for Aranesp

Other warnings & precautions

Aranesp Black Box Warning

No black box warning on record for Aranesp

Other warnings & precautions